Monness, Crespi, Hardt Initiates Coverage on Incyte (INCY) with a Buy
More News related to INCY
- Oppenheimer Initiates Coverage on Incyte Corp (INCY) with an Outperform
- Incyte to Present at the Cowen and Company 30th Annual Health Care Conference
- Incyte Corporation (INCY) Posts Q4 Loss of $0.41 Ex-Items; Guides FY10 Revs
- Incyte Reports 2009 Financial Results; Strengthens Balance Sheet; Provides 2010 Financial Guidance
- Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
More News related to New Coverage
- AstraZeneca (AZN) Comments on LABA Advisory Meetings; Confident in SYMBICORT
- Pfizer (PFE) Anounces Two Phase 3's of Sutent Miss End-Points
- Watson Pharma (WPI) Gets U.S. FDA Approval for TRELSTAR 22.5-mg Prostate Cancer Treatment
- Neoprobe Corp (NEOP) Announces Meeting with U.S. FDA Regarding Lymphoseek Phase 3
- Abbott (ABT) Seeks U.S. FDA Approval for Lupron Six-Month 45-mg Formulation Prostate Cancer Treatment
Monness, Crespi, Hardt initiates coverage on Incyte (Nasdaq: INCY) with a Buy rating.
To see all the upgrades/downgrades on shares of INCY, visit our Analyst Ratings page.
Incyte Corporation (Incyte) is a drug discovery and development company focused on developing small molecule drugs to treat serious unmet medical needs.
Related Categories
New CoverageStocks Mentioned
+0.65Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
